Hepatitis E: a neglected threat.
Hepatitis E, responsible for explosive waterborne outbreaks and sporadic cases of acute hepatitis in developing countries, affects predominantly young adults and has a fatality rate as high as 25% in pregnant women. No effective treatment exists for hepatitis E; however, a vaccine using a baculovirus-expressed recombinant hepatitis E capsid protein was recently studied in Nepal. In this review, the progress made in hepatitis E research and the recently concluded vaccine trial of the recombinant protein vaccine are briefly discussed.
Myint
Khin Saw Aye
KS
Department of Virology, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. myintk@afrims.org
Gibbons
Robert V
RV
D000328:Adult; D002986:Clinical Trials as Topic; D003906:Developing Countries; D019353:Endemic Diseases / Q000517:prevention & control; D005260:Female; D016751:Hepatitis E / Q000453:epidemiology* / Q000517:prevention & control; D016752:Hepatitis E virus / Q000276:immunology; D006801:Humans; D008297:Male; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
D014761:Viral Hepatitis Vaccines